vs
Amphastar Pharmaceuticals, Inc.（AMPH）与GRID DYNAMICS HOLDINGS, INC.（GDYN）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是GRID DYNAMICS HOLDINGS, INC.的1.8倍（$183.1M vs $104.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs -1.4%，领先14.8%），GRID DYNAMICS HOLDINGS, INC.同比增速更快（3.7% vs -1.8%），过去两年GRID DYNAMICS HOLDINGS, INC.的营收复合增速更高（12.0% vs 3.2%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Escape Dynamics Inc.是一家总部位于科罗拉多州的科技企业，活跃于2010年至2015年，核心业务方向是研发可单级入轨、依靠电磁驱动的可重复使用航天飞机，并推动该项目实现商业化落地。
AMPH vs GDYN — 直观对比
营收规模更大
AMPH
是对方的1.8倍
$104.1M
营收增速更快
GDYN
高出5.5%
-1.8%
净利率更高
AMPH
高出14.8%
-1.4%
两年增速更快
GDYN
近两年复合增速
3.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $104.1M |
| 净利润 | $24.4M | $-1.5M |
| 毛利率 | 46.8% | 34.8% |
| 营业利润率 | 19.4% | 61.7% |
| 净利率 | 13.3% | -1.4% |
| 营收同比 | -1.8% | 3.7% |
| 净利润同比 | -35.7% | -150.6% |
| 每股收益（稀释后） | $0.51 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHGDYN
| Q1 26 | — | $104.1M | ||
| Q4 25 | $183.1M | $106.2M | ||
| Q3 25 | $191.8M | $104.2M | ||
| Q2 25 | $174.4M | $101.1M | ||
| Q1 25 | $170.5M | $100.4M | ||
| Q4 24 | $186.5M | $100.3M | ||
| Q3 24 | $191.2M | $87.4M | ||
| Q2 24 | $182.4M | $83.0M |
净利润AMPHGDYN
| Q1 26 | — | $-1.5M | ||
| Q4 25 | $24.4M | $306.0K | ||
| Q3 25 | $17.4M | $1.2M | ||
| Q2 25 | $31.0M | $5.3M | ||
| Q1 25 | $25.3M | $2.9M | ||
| Q4 24 | $38.0M | $4.5M | ||
| Q3 24 | $40.4M | $4.3M | ||
| Q2 24 | $37.9M | $-817.0K |
毛利率AMPHGDYN
| Q1 26 | — | 34.8% | ||
| Q4 25 | 46.8% | 34.0% | ||
| Q3 25 | 51.4% | 33.3% | ||
| Q2 25 | 49.6% | 34.1% | ||
| Q1 25 | 50.0% | 36.8% | ||
| Q4 24 | 46.5% | 36.9% | ||
| Q3 24 | 53.3% | 37.4% | ||
| Q2 24 | 52.2% | 35.6% |
营业利润率AMPHGDYN
| Q1 26 | — | 61.7% | ||
| Q4 25 | 19.4% | 0.5% | ||
| Q3 25 | 13.2% | -0.2% | ||
| Q2 25 | 24.2% | -0.1% | ||
| Q1 25 | 21.9% | -2.0% | ||
| Q4 24 | 24.2% | 1.3% | ||
| Q3 24 | 29.8% | 2.4% | ||
| Q2 24 | 30.3% | 0.0% |
净利率AMPHGDYN
| Q1 26 | — | -1.4% | ||
| Q4 25 | 13.3% | 0.3% | ||
| Q3 25 | 9.0% | 1.1% | ||
| Q2 25 | 17.8% | 5.2% | ||
| Q1 25 | 14.8% | 2.9% | ||
| Q4 24 | 20.4% | 4.5% | ||
| Q3 24 | 21.1% | 4.9% | ||
| Q2 24 | 20.8% | -1.0% |
每股收益（稀释后）AMPHGDYN
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $0.51 | $0.01 | ||
| Q3 25 | $0.37 | $0.01 | ||
| Q2 25 | $0.64 | $0.06 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.74 | $0.06 | ||
| Q3 24 | $0.78 | $0.05 | ||
| Q2 24 | $0.73 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $327.5M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $530.1M |
| 总资产 | $1.6B | $605.0M |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHGDYN
| Q1 26 | — | $327.5M | ||
| Q4 25 | $282.8M | $342.1M | ||
| Q3 25 | $276.2M | $338.6M | ||
| Q2 25 | $231.8M | $336.8M | ||
| Q1 25 | $236.9M | $325.5M | ||
| Q4 24 | $221.6M | $334.7M | ||
| Q3 24 | $250.5M | $231.3M | ||
| Q2 24 | $217.8M | $256.0M |
总债务AMPHGDYN
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
股东权益AMPHGDYN
| Q1 26 | — | $530.1M | ||
| Q4 25 | $788.8M | $542.1M | ||
| Q3 25 | $776.7M | $537.7M | ||
| Q2 25 | $757.5M | $532.2M | ||
| Q1 25 | $751.3M | $517.4M | ||
| Q4 24 | $732.3M | $517.8M | ||
| Q3 24 | $727.7M | $400.2M | ||
| Q2 24 | $713.3M | $388.4M |
总资产AMPHGDYN
| Q1 26 | — | $605.0M | ||
| Q4 25 | $1.6B | $612.9M | ||
| Q3 25 | $1.7B | $613.2M | ||
| Q2 25 | $1.6B | $608.9M | ||
| Q1 25 | $1.6B | $590.9M | ||
| Q4 24 | $1.6B | $592.2M | ||
| Q3 24 | $1.5B | $477.3M | ||
| Q2 24 | $1.5B | $443.6M |
负债/权益比AMPHGDYN
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | — |
| 自由现金流经营现金流 - 资本支出 | $24.6M | — |
| 自由现金流率自由现金流/营收 | 13.4% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | 1.35× | — |
| 过去12个月自由现金流最近4个季度 | $121.2M | — |
8季度趋势，按日历期对齐
经营现金流AMPHGDYN
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $9.9M | ||
| Q3 25 | $52.6M | $7.0M | ||
| Q2 25 | $35.6M | $14.4M | ||
| Q1 25 | $35.1M | $9.4M | ||
| Q4 24 | $29.0M | $7.1M | ||
| Q3 24 | $60.0M | $9.2M | ||
| Q2 24 | $69.1M | $10.7M |
自由现金流AMPHGDYN
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $6.1M | ||
| Q3 25 | $47.2M | $2.9M | ||
| Q2 25 | $25.0M | $10.2M | ||
| Q1 25 | $24.4M | $6.0M | ||
| Q4 24 | $16.6M | $4.4M | ||
| Q3 24 | $46.2M | $5.9M | ||
| Q2 24 | $63.1M | $8.0M |
自由现金流率AMPHGDYN
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 5.7% | ||
| Q3 25 | 24.6% | 2.8% | ||
| Q2 25 | 14.3% | 10.1% | ||
| Q1 25 | 14.3% | 6.0% | ||
| Q4 24 | 8.9% | 4.4% | ||
| Q3 24 | 24.1% | 6.8% | ||
| Q2 24 | 34.6% | 9.7% |
资本支出强度AMPHGDYN
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 3.6% | ||
| Q3 25 | 2.8% | 3.9% | ||
| Q2 25 | 6.1% | 4.1% | ||
| Q1 25 | 6.3% | 3.3% | ||
| Q4 24 | 6.7% | 2.6% | ||
| Q3 24 | 7.2% | 3.7% | ||
| Q2 24 | 3.3% | 3.2% |
现金转化率AMPHGDYN
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 32.34× | ||
| Q3 25 | 3.03× | 5.92× | ||
| Q2 25 | 1.15× | 2.73× | ||
| Q1 25 | 1.39× | 3.21× | ||
| Q4 24 | 0.76× | 1.56× | ||
| Q3 24 | 1.48× | 2.15× | ||
| Q2 24 | 1.82× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GDYN
暂无分部数据
